Denka Company Limited

Kumamoto University

Denka Seiken Co., Ltd.

Ryotaro Mitsumata

Shogo Misumi

Naoki Kishimoto

Takuma Gotanda

Nagisa Nakata

Noriyuki Izutani

Asumi Kanda

Provided are an adjuvant useful for preparing a vaccine having high efficacy and high safety, and a vaccine composition comprising the adjuvant. The adjuvant comprises a peptide nucleic acid to which a cell penetrating peptide is bound.

Adjuvant based on peptide nucleic acid

An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.

Inactivated whole-virus influenza vaccine and method for preparing same

A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.

Mucosal adjuvant

Disclosed is a novel method for measuring haemagglutinin of an influenza virus, which can construct an assay system in a shorter period of time than a sandwich immunoassay method using two kinds of anti-haemagglutinin antibodies. The method for measuring haemagglutinin of an influenza virus is achieved by a sandwich immunoassay method comprising sandwiching the haemagglutinin between a lectin which binds to the haemagglutinin but does not bind to an antibody, and an anti-haemagglutinin antibody which undergoes antigen-antibody reaction with the haemagglutinin.

Growing community of inventors

Gosen, Japan

Ryotaro Mitsumata